Free tool
FAERS Monitor: Paclitaxel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216338 or its brand name (Paclitaxel, Paclitaxel). Reports on generic versions are filed under their own applications.
Reports
84,326
Serious
81,765
97% of reports
Hospitalization
34,078
Death reported
11,621
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea4,733
- dyspnoea4,676
- neutropenia4,628
- off label use4,561
- diarrhoea4,383
- anaemia4,036
- malignant neoplasm progression3,938
- myelosuppression3,678
- disease progression3,478
- fatigue3,475
- neuropathy peripheral3,433
- pyrexia3,235
- vomiting3,198
- febrile neutropenia3,176
- drug ineffective2,641
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 626 |
| 2005 | 832 |
| 2006 | 599 |
| 2007 | 576 |
| 2008 | 812 |
| 2009 | 968 |
| 2010 | 990 |
| 2011 | 1,649 |
| 2012 | 2,062 |
| 2013 | 2,215 |
| 2014 | 1,795 |
| 2015 | 2,370 |
| 2016 | 2,931 |
| 2017 | 3,194 |
| 2018 | 4,835 |
| 2019 | 4,669 |
| 2020 | 4,850 |
| 2021 | 5,551 |
| 2022 | 7,668 |
| 2023 | 8,071 |
| 2024 | 9,609 |
| 2025 | 10,146 |
| 2026 | 7,307 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,969,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 3,678 | 28.3 | 27.3 | 86,940 |
| febrile neutropeniaSignal | 3,176 | 12.5 | 12.1 | 32,060 |
| malignant neoplasm progressionSignal | 3,938 | 9.9 | 9.6 | 30,567 |
| neuropathy peripheralSignal | 3,433 | 9.3 | 9.0 | 24,619 |
| neutropeniaSignal | 4,628 | 8.8 | 8.5 | 30,895 |
| disease progressionSignal | 3,478 | 7.5 | 7.3 | 19,195 |
| anaemiaSignal | 4,036 | 5.4 | 5.2 | 14,176 |
| pyrexiaSignal | 3,235 | 2.3 | 2.3 | 2,511 |
| dyspnoeaSignal | 4,676 | 2.1 | 2.0 | 2,631 |
| vomiting | 3,198 | 1.7 | 1.6 | 938 |
| diarrhoea | 4,383 | 1.7 | 1.6 | 1,289 |
| nausea | 4,733 | 1.5 | 1.5 | 799 |
| off label use | 4,561 | 1.3 | 1.3 | 329 |
| fatigue | 3,475 | 1.1 | 1.1 | 42 |
| drug ineffective | 2,641 | 0.5 | 0.5 | 1,415 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.